A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs RPL 554 (Primary) ; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 18 May 2016 Status changed from active, no longer recruiting to completed, as per results presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results (n = 25) presented at the 112th International Conference of the American Thoracic Society.
- 27 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History